Answers are grounded in this paper and cite their sources.
To the Editor: Schlumberger et al. (Feb. 12 issue) 1 report that lenvatinib, as compared with placebo, showed significant improvements in progression-free survival and response rate among patients with radioiodine-refractory thyroid cancer. However, 76% of the patients had grade 3 or higher treatment-related toxic events, and there were an increased number of deaths during lenvatinib treatment. Furthermore, 6 of the 20 deaths in the lenvatinib group appeared to be treatment-related. Therefore, it is crucial to identify predictive biomarkers to identify patients who will benefit most from lenvatinib treatment. These markers might be found at the genetic level, 2 although the presence of BRAF or RAS mutations did not predict a benefit for lenvatinib in this study. 1 Alternatively, the occurrence of adverse events might act as a surrogate biomarker of drug activity because the occurrence of treatment-related toxic effects is associated with pharmacodynamic effects of the drug. 2-4 Recently, it has been suggested that such factors as tumor shrinkage and a severe grade of hypertension, proteinuria, and fatigue induced by lenvatinib were significantly correlated with the area under the curve for the dosing interval. 5 Therefore, it would be interesting to know whether the authors found a correlation between adverse events and treatment outcome.
No takes yet. Share an insight, caveat, or question.
Schlumberger et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: